Pipeline

SB 11285: Improving Checkpoint Inhibitor (CPI) outcomes

Although many patients respond to PD-1 therapies, in some patients, the PD-1 blockade is not enough to activate immune cells. Activation of the STING (Stimulator of Interferon Genes) pathway induces both innate and adaptive immunity and subsequent activation of cytotoxic T cells and NK cells. The first generation of STING agonists were generally delivered intratumorally with limited success. SB 11285 can be administered intravenously and has promising cellular uptake into immune cells. 

Our Approach to Improving Checkpoint Inhibitor Outcomes with a STING agonist 

  • Second generation STING agonist for intravenous administration
  • Preclinical studies indicate potential advantages over intratumoral STING agonists
  • Phase 1/2 trial ongoing including combination with PD-L1 mAb

SB STING Agonist